Holloway Jean F sold $28K of AORT

Holloway Jean F (SVP, General Counsel) sold 977 shares of ARTIVION, INC. (AORT) at $28.49 on 2026-08-12.

Original reporting
SEC EDGAR · Holloway Jean F
Published Aug 12, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
medium confidence
Mentioned
$AORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new operational, financial, or regulatory information about Artivion.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no direct fundamental catalyst in the filing.

03

What to watch

The article provides only the sale size and price, not the insider’s broader trading history, tax situation, or whether other insiders or institutions acted around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12, after-hours disclosure window

Background

This is an SEC Form 4 insider transaction disclosure for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralMedium confidence
Context

Artivion disclosed an insider open-market sale by SVP and General Counsel Holloway Jean F of 977 shares at $28.49 on 2026-08-12.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction (open-market sale) with no 10b5-1 plan and no accompanying company-specific news, so the incremental information is modest.

Market effects

No clear sector read-through from a single insider sale without additional company or regulatory developments.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or tax needs; absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • ARTIVION, INC.

    Company whose insider transaction was reported on Form 4.

  • Holloway Jean F

    SVP and General Counsel who sold 977 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMedAI 8/10

Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus

Artivion Inc. reported Q3 2026 earnings, highlighting a gross margin decline to 61.4% due to mix, ramp costs, and charges. CEO Pat Mackin expects a gradual Nexus U.S. launch in 2027. Onyx growth slowed to 13%, with mid-teens full-year growth expected. The company aims to reduce leverage through EBITDA growth, with free cash flow positive in 2027. Core stent graft growth dipped below mid-teens, but is seen as a solid double-digit business.

$AORTHighAI 8/10

Artivion (AORT) Q3 2026 Earnings Call Transcript

Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.

$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.